Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared the first ...
Sarepta Therapeutics (SRPT) added ~25% in the morning hours on Wednesday after the company posted initial data from Phase 1/2 ...
Sarepta (SRPT) stock rises on positive Phase 1/2 siRNA trial data showing muscle delivery, biomarker activity, and safety in ...
Sarepta Therapeutics (NASDAQ:SRPT) shares rose 14% following the company’s release of initial clinical data from its siRNA pipeline targeting facioscapulohumera ...
InvestorsHub on MSN
Sarepta shares jump after early clinical data from siRNA programs
Shares of Sarepta Therapeutics (NASDAQ:SRPT) climbed about 14% after the company released preliminary clinical results from ...
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares surged almost 26% to about $22 after the biotechnology company shared early ...
A study published in the Journal of Controlled Release ("NMR-based analysis of impact of siRNA mixing conditions on internal structure of siRNA-loaded LNP"), led by Assistant Professor Keisuke Ueda ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results